Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
K.D. Pagana, T.J. Pagana, T.N. Pagana.
Guía de pruebas diagnósticas y de laboratorio.
13.ª ed., Elsevier España, (2018), pp. 747-751
[2]
Balcells. La clínica y el laboratorio. Cap. 2, 22.ª ed., Elsevier España, pp. 35-107
[3]
D.J. Dietzen.
Amino Acids, Peptides, and Proteins.
Textbook of Clinical Chemistry and Molecular Diagnostics. Cap 28: Aminoacids, Peptids and Proteins, 6.ª ed., Elsevier, pp. 373-403.e5
[4]
T.X. O’Connell, T.J. Horita, B. Kasravi.
Understanding and interpreting serum protein electrophoresis.
Am Fam Physician., (2005), 71 pp. 105-112
[5]
E. Bergon, I. Miranda, E. Miravalles.
Blood protein electrophoresis, instrumentation.
Clin Chem Lab Med., (2005), 43 pp. 721-723
[6]
T. Peters.
All about albumin: serum albumin-biochemistry, genetics, and medical applications.
AACC Press, (1996),
[7]
H.J. Moshage, J.A. Janssen, J.H. Franssen, J.C. Hafkenscheid, S.H. Yap.
Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.
J Clin Invest., (1987), 79 pp. 1635-1641
[8]
S.B. Umar, J.K. DiBaise.
Protein-losing enteropathy: case illustrations and clinical review.
Am J Gastroenterol., (2010), 105 pp. 43-49
[9]
M.H. Dominiczak, W.D. Fraser.
Blood and Plasma Proteins.
Dominiczak. Medical Biochemistry. Cap 4: Blood and Plasma Proteins., 4.ª ed., Elsevier, pp. 31-39
[10]
C. Gabay, I. Kushner.
Acute-phase proteins and other systemic responses to inflammation.
N Engl J Med., (1999), 340 pp. 448-454
[11]
M. El-Bahrawy.
Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract.
Eur J Cancer., (2010), 46 pp. 1317-1322
[12]
X. Liu, Y. Cheng, W. Sheng, H. Lu, Y. Xu, Z. Long, et al.
Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases.
J Surg Oncol., (2010), 102 pp. 249-255
[13]
R.K. Sterling, E.C. Wright, T.R. Morgan, L.B. Seeff, J.C. Hoefs, A.M. Di Bisceglie, et al.
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
Am J Gastroenterol., (2012), 107 pp. 64-74
[14]
A.M. Di Bisceglie, R.K. Sterling, R.T. Chung, J.E. Everhart, J.L. Dienstag, H. Bonkovsky, et al.
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
J Hepatol., (2005), 43 pp. 434-441
[15]
F.E. Bredaki, L.C. Poon, C. Birdir, D. Escalante, K.H. Nicolaides.
First-trimester screening for neural tube defects using alpha-fetoprotein.
Fetal Diagn Ther., (2012), 31 pp. 109-114
[16]
D.A. Aitken, G. McCaw, J.A. Crossley, E. Berry, J.M. Connor, K. Spencer, et al.
First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects.
Prenat Diagn., (1993), 13 pp. 681-689
[17]
K. Spencer, A. Khalil, L. Brown, I. Mills, H. Horne.
First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida.
Prenat Diagn., (2014), 34 pp. 168-171
[18]
C.C. Chernecky, B.J. Berger.
Laboratory Tests and Diagnostic Procedures.
6.ª ed., Elsevier, (2013),
[19]
U. Hatipoğlu, J. Stoller.
α1-Antitrypsin Deficiency.
Clin Chest Med, (2016), 37 pp. 487-504
[20]
M. Bravo García-Morato, B. Padilla-Merlano, P. Nozal, M. Espiño, C. Juárez, L.M. Villar, et al.
Guía de laboratorio para el diagnóstico y seguimiento de pacientes con gammapatías monoclonales.
Rev Clin Esp., (2016), 216 pp. 128-134
[21]
J. Bird, J. Behrens, J. Westin, I. Turesson, M. Drayson, R. Beetham, et al.
Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Br J Haematol., (2009), 147 pp. 22-42
[22]
J.A. Katzmann, A. Dispenzieri, R.A. Kyle, M.R. Snyder, M.F. Plevak, D.R. Larson, et al.
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Mayo Clin Proc., (2006), 81 pp. 1575-1579
[23]
C.A. Hutchison, S. Harding, P. Hewins, G.P. Mead, J. Townsend, A.R. Bradwell, et al.
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.
Clin J Am Soc Nephrol., (2008), 3 pp. 1684-1690
[24]
J.A. Katzmann, R.J. Clark, R.S. Abraham, S. Bryant, J.F. Lymp, A.R. Bradwell, et al.
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Clin Chem., (2002), 48 pp. 1437-1444
[25]
P. Vermeersch, L. Van Hoovels, M. Delforge, G. Mariën, X. Bossuyt.
Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Br J Haematol., (2008), 143 pp. 496-502
[26]
G. Pratt.
The evolving use of serum free light chain assays in haematology.
Br J Haematol., (2008), 141 pp. 413-422
[27]
G.P. Mead, H.D. Carr-Smith, M.T. Drayson, G.J. Morgan, J.A. Child, A.R. Bradwell.
Serum free light chains for monitoring multiple myeloma.
Br J Haematol., (2004), 126 pp. 348-354
[28]
F. van Rhee, V. Bolejack, K. Hollmig, M. Pineda-Roman, E. Anaissie, J. Epstein, et al.
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Blood., (2007), 110 pp. 827-832
[29]
R.S. Abraham, J.A. Katzmann, R.J. Clark, A.R. Bradwell, R.A. Kyle, M.A. Gertz.
Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Am J Clin Pathol., (2003), 119 pp. 274-278
[30]
R.G. Owen, S.P. Treon, A. Al-Katib, R. Fonseca, P.R. Greipp, M.L. McMaster, et al.
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Semin Oncol., (2003), 30 pp. 110-115
[31]
S.V. Rajkumar, M.A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini, M.V. Mateos, et al.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol., (2014), 15 pp. e538-e548
[32]
R.A. Kyle, S.V. Rajkumar.
Monoclonal gammopathy of undetermined significance.
Br J Haematol., (2006), 134 pp. 573-589
[33]
R.K. Wadhera, S.V. Rajkumar.
Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.
Mayo Clin Proc., (2010), 85 pp. 933-942
[34]
L.J. Melton 3rd, S.V. Rajkumar, S. Khosla, S.J. Achenbach, A.L. Oberg, R.A. Kyle.
Fracture risk in monoclonal gammopathy of undetermined significance.
J Bone Miner Res., (2004), 19 pp. 25-30
[35]
J.P. Bida, R.A. Kyle, T.M. Therneau, L.J. Melton 3rd, M.F. Plevak, D.R. Larson, et al.
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.
Mayo Clin Proc., (2009), 84 pp. 685-693
[36]
R.A. Kyle, S.V. Rajkumar.
Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Br J Haematol., (2007), 139 pp. 730-743
[37]
S.V. Rajkumar, D. Larson, R.A. Kyle.
Diagnosis of smoldering multiple myeloma.
N Engl J Med., (2011), 365 pp. 474-475
[38]
R.A. Kyle, R.A. Robinson, J.A. Katzmann.
The clinical aspects of biclonal gammopathies. Review of 57 cases.
Am J Med., (1981), 71 pp. 999-1008
[39]
J.P. Fermand, J.C. Brouet.
Heavy-chain diseases.
Hematol Oncol Clin North Am., (1999), 13 pp. 1281-1294
[40]
D.L. Wahner-Roedler, T.E. Witzig, L.L. Loehrer, R.A. Kyle.
Gamma-heavy chain disease: review of 23 cases.
Medicine (Baltimore)., (2003), 82 pp. 236-250
[41]
Pastrana J, Landecho MF, Alegre F, Huerta A, González A. Bioquímica hemática. En: Balcells, ed. La clínica y el laboratorio. Cap. 2. 22.ª ed. Madrid: Elsevier España; 2015. p. 35-107.
[42]
V. González de la Calle, M. Pérez-Andrés, N. Puig Morón.
Inmunodeficiencias primarias.
Medicine., (2016), 12 pp. 1191-1200
[43]
D.S. Rojas-Torres, D.K. Bastidas-Yaguana, L. Sierra-Santos, A.L. Aguilar-Shea.
Importancia del déficit selectivo de inmunoglobulina A.
Semergen., (2014), 40 pp. e65-e68
